The latest price target for Talis Biomedical (NASDAQ:TLIS) was reported by BTIG on August 16, 2023. The analyst firm set a price target for $5.00 expecting TLIS to fall to within 12 months (a possible -40.90% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Talis Biomedical (NASDAQ:TLIS) was provided by BTIG, and Talis Biomedical maintained their sell rating.

There is no last upgrade for Talis Biomedical

The last downgrade for Talis Biomedical Corp happened on March 18, 2022 when BTIG changed their price target from N/A to $1 for Talis Biomedical Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Talis Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Talis Biomedical was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.

While ratings are subjective and will change, the latest Talis Biomedical (TLIS) rating was a maintained with a price target of $0.35 to $5.00. The current price Talis Biomedical (TLIS) is trading at is $8.46, which is out of the analyst’s predicted range.